Study Reference

Design

No of Patients

G-CSF Dose (μg/kg/day)

Treatment Initiated

Follow-Up

Outcomes

[95]    (MAGIC Trial)

Phase-2, Randomised, Controlled

n=7 BMNC; n=3 GCSF only; n=1 control

10 for 4 days

4 days prior to PCI

6 months.

GCSF treatment is safe. Increased CD34⁺ cell mobilization. GCSF alone has no functional benefit. BMNC transplantation significantly increased EF & ESV. Trial stopped due to significant restenosis rate.

[100]

Non-randomised, Open-labelled

n=14 GCSF; n=9 control

10 for 7 days

48 hours post-PCI

3 and 12 months.

GCSF is safe. Increased CD34⁺ cells/leukocytes. Trend towards increased EF and significant increase in WMS & perfusion vs. control.

[96]
(FIRSTLINE-AMI trial)

Randomised, Controlled

n=25 GCSF; n=25 control

10 for 6 days

90 minutes post-PCI

6 months.

GCSF is safe. Increased CD34⁺ cell mobilization. EF, WMS & viability significantly improved vs. control. 4 & 5 patients in GCSF & control had restenosis, respectively.

[101]

Randomised, placebo-controlled

n=8 GCSF; n=8 control

5 for 4 days

37 hours post-PCI

6 months.

GCSF is safe. Increased mobilization of CD34⁺ cells. No significant benefit with lone GCSF.

[102]        (G-CSF-STEMI Trial)

Phase-2, Randomised, double-blind, placebo- controlled

n=19 GCSF; n=21 control

10 for 5 days

32 hours post-PCI

3 and 6 months.

GCSF is safe. Increased CD34⁺ cells. No functional benefit with lone GCSF. No difference if restenosis rate vs. control.

[98] (REVIVAL-2 Trial)

Randomised, Placebo-controlled

n=56 GCSF; n=58 control

10 for 5 days

4-5 days post-PCI

4-6 months. Angiography at

GCSF is safe. Increased CD34⁺ cells. No functional benefit with lone GCSF. No difference in restenosis rate.

[99] (STEMMI Trial)

Phase-2, randomised, double-blind, placebo-controlled

n=33 GCSF; n=37 control

10 for 6 days

10-60 hours post-PCI

6 months.

GCSF is safe. Increased CD34⁺ cells and MSCs. No functional benefit with lone GCSF. No increase in restenosis rate with GCSF.